PDC line Pharma

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic cells (PDC*line). Its breakthrough technology, PDC*vac, is more potent than conventional Dendritic Cell-based vaccines, scalable, versatile to any cancer type, and synergistic with checkpoint inhibitors such as anti-PD-1. The market potential for PDC*vac is estimated in the range of €3BN to €4.5BN. PDC*line Pharma's leading candidate is in clinical phase 1 studies for the treatment of melanoma (PDC*mel). Its next-in-line candidate is in preclinical stage for the treatment of lung cancer (PDC*lung). The company won several awards, including the 2015 Life Sciences Grand Prize of the French start-up competition Tremplin Entreprises, and is collecting €2.7M in pre/seed financing.